m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02227)
Name
Quercetin
Synonyms
2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one dihydrate; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; 3',4',5,7-Tetrahydroxyflavan-3-ol; 3',4',5,7-tetrahydroxyflavon-3-ol; 3,3',4',5,7-Pentahydroxyflavone; 3,3',4',5,7-Pentahydroxyflavone dihydrate; 3,3',4,5,7-Pentahydroxyflavone; 3,5,7,3',4'-Pentahydroxyflavone; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one; C.I . natural yellow 10; C.I. 75670; C.I. Natural Yellow 10; C.I. Natural red 1; C.I. Natural yellow 10 & 13; CI Natural Yellow 10; CU-01000012502-3; Cyanidelonon 1522; Flavin meletin; KSC-10-126; KSC-23-76; KUC104418N; KUC107684N; Kvercetin; Kvercetin [Czech]; LIM-5662; LNS-5662; Meletin; MixCom3_000183; Natural Yellow 10; P0042; Q 0125; QUE; Quercetin content; Quercetin dihydrate; Quercetine; Quercetol; Quercitin; Quertin; Quertine; Sophoretin; T-Gelb bzw. grun 1; TNP00070; TNP00089; Xanthaurine
    Click to Show/Hide
Status
Approved
Structure
Formula
C15H10O7
InChI
1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H
InChIKey
REFJWTPEDVJJIY-UHFFFAOYSA-N
PubChem CID
5280343
VARIDT Drug ID
DR00225
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Quercetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quercetin through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
Glucose transporter type 1 (SLC2A1)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for Quercetin. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Quercetin through regulating the expression of Glucose transporter type 1 (SLC2A1). [3], [4]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for Quercetin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Quercetin through regulating the expression of Glucose transporter type 1 (SLC2A1). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for Quercetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quercetin through regulating the expression of Glucose transporter type 1 (SLC2A1). [3], [4]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Quercetin. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Quercetin through regulating the expression of P-glycoprotein 1 (ABCB1). [5], [6]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Quercetin. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Quercetin through regulating the expression of P-glycoprotein 1 (ABCB1). [1], [6]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. doi: 10.1016/j.canlet.2015.10.010. Epub 2015 Oct 20.
Ref 3 m(6)A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 2020 Apr 3;19(1):72. doi: 10.1186/s12943-020-01190-w.
Ref 4 Oral Bioavailability and Disposition of Phytochemicals
Ref 5 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 6 Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med. 2004 Mar 1;36(5):592-604.